Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs
After months of tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state AIDS Drug Assistance Programs, an outcome that lessens the financial strains for agencies that are relied on by many people on low incomes. Earlier this year, the company sought to boost prices…